Abstract: A method of assessing soil heave includes providing a plurality of determined values of a shear modulus of soil, the determined values being values of the shear modulus of the soil at different times; and determining a change over time in the shear modulus of the soil, based on the plurality of determined values of the shear modulus of the soil. The soil may have been treated by adding a stabilizer to the soil. The soil may be hydrated. A system for assessing soil heave includes a bender element disposed in soil, for determining a change over time of a shear modulus of the soil, and a time domain reflectometer probe disposed in the soil, for determining a change over time of moisture content of the soil. The determined change over time of the shear modulus and the determined change over time of the moisture content are used to assess heaving of the soil.

Abstract: Compositions and methods for inhibiting the DNA repair protein complex, ERCC1-XPF, and methods to enhance clinical responses to anticancer drugs that interact with DNA such as cisplatin, and to overcome drug resistance due to DNA repair mechanisms, are described.

Abstract: A device or class of devices that provides a mechanism for controlling charge current flow in transistors that employs collective magnetic effects to overcome voltage limitations associated with single-particle thermionic emission as in conventional MOSFETs. Such a device may include two or more magnetic stacks with an easy-in-plane ferromagnetic film sandwiched between oppositely magnetically oriented perpendicular magnetization anisotropy (PMA) ferromagnets. Each stack includes two non-magnetic layers separating the easy-plane ferromagnetic film from the PMA layers. Charge current flow through one of these stacks controls the current-voltage negative differential resistance characteristics of the second stack through collective magnetic interactions. This can be exploited in a variety of digital logic gates consuming less energy than conventional CMOS integrated circuits.

Abstract: A driving assistance control device for a vehicle includes: a moving object detection sensor configured to detect a moving object moving along a roadside in a traveling direction of the vehicle; a driving operation detection sensor configured to detect a driving operation of a driver; an actuator; and an Electronic Control Unit configured to perform automatic steering control of the vehicle by the actuator to avoid the moving object based on a detection result of the moving object, the Electronic Control Unit being configured to start the automatic steering control based on a driving steering of the driver after the moving object is detected.

Abstract: A method for producing cell aggregates includes culturing cells while suspending the cells in a liquid culture medium comprising a lysophospholipid. A composition includes a lysophospholipid, wherein the composition is a liquid culture medium or a composition added to a liquid culture medium.

Abstract: The present invention includes a treatment system and methods for removing waste or other agents from a fluid stream, the system comprising: an inlet flow path for receiving a fluid stream from a source outside the treatment system; a vessel for containing the fluid stream, the vessel comprising a permeable filter configured for biological and physical treatment of the fluid stream, the filter comprising one or more nano-thin film or polymer composite layers of carbon materials assembled in sp2 hybridized structures comprising carbon-carbon bonds, wherein the waste or agent is removed as it flows through pores in the film composite; and a drain fluidly connected to the vessel for discharging treated fluid stream from the vessel from which the waste or agents have been removed.

Abstract: Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.

Abstract: A nanofiber forest on a substrate can be patterned to produce a patterned assembly of nanofibers that can be drawn to form nanofiber sheets, ribbons, or yarns.

Abstract: The present invention is directed to a versatile and high performance zwitterionic CP platform, which integrates all desired functions into one material. This zwitterionic CP consists of the conducting backbone and multifunctional zwitterionic side chains. Non-conducting zwitterionic materials gain electronic conductivity through the conducting backbone and CPs obtain excellent biocompatibility, sensitivity to environmental stimuli and controllable antifouling properties via multifunctional zwitterionic side chains. Unique properties from two distinct materials (conducting materials and zwitterionic materials) are integrated into one material without sacrificing any properties. This platform can potentially be adapted for a range of applications (e.g. bioelectronics, tissue engineering, wound healing, robotic prostheses, biofuel cell, etc.), which all require high performance conducting materials with excellent antifouling/biocompatibility at complex biointerfaces.

Abstract: Systems and methods for stimulating tissue. Exemplary embodiments include systems and methods configured to maintain one electrode at a fixed voltage potential and switching a second electrode between different fixed voltage potentials.

Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo[2,3-b]pyridines having Formula IX Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Abstract: An object of the present invention is to provide a VEGFR2 inhibitor peptide having high specificity and available at a low cost.

Abstract: Methods, systems and devices that generate differential axial transport in a fluidic device having at least one fluidic sample separation flow channel and at least one ESI emitter in communication with the at least one sample separation flow channel. In response to the generated differential axial transport, the at least one target analyte contained in a sample reservoir in communication with the sample separation channel is selectively transported to the at least one ESI emitter while inhibiting transport of contaminant materials contained in the sample reservoir toward the at least one ESI emitter thereby preferentially directing analyte molecules out of the at least one ESI emitter. The methods, systems and devices are particularly suitable for use with a mass spectrometer.

Abstract: A nanofiber forest on a substrate can be patterned to produce a patterned assembly of nanofibers that can be drawn to form nanofiber sheets, ribbons, or yarns.

Abstract: Various implementations of a patient monitoring assembly may be useful in preventing pressure ulcers, monitoring of air cushion inflation, estimating physical activity and energy expenditure and managing body weight of a patient seated on the assembly. The patient monitoring assembly may be installed on a manual or powered wheelchair, for example, and continuously monitors and provides feedback to the patient and/or caregiver about whether the patient is engaging in pressure relief activities while seated on a cushion of the assembly, whether the patient's activities are in accordance with clinical guidelines for pressure relief, the amount of calories expended over a period of time and the weight and weight distribution of the patient seated on the assembly. The feedback may be provided in substantially real time via an interface on the wheelchair and/or via a remotely located computing device.

Abstract: A fractionation system comprising means for forming a three dimensional optical lattice that is operable to separate particles that have different physical characteristics. Preferably, the wells of the optical lattice are interlinked. For example, the wells may be linked in such a manner as to provide deflection greater than or equal to 15 degrees.

Abstract: A pipelined SAR ADC includes a first stage and passive residue transfer is used to boost a conversion speed. Owing to the passive residue transfer, the first stage may be released during a residue amplification phase, cutting down a large part of the first-stage timing budget. An asynchronous timing scheme may also be adopted in both the first- and second-stage SAR ADCs to maximize the overall conversion speed. Lastly, a dynamic amplifier with proposed PVT stabilization technique may be employed to further save power consumption and improve the conversion speed simultaneously.

Abstract: Underwater adhesive materials, methods of making the same, and methods of using the same are described.

Abstract: The invention relates to an ophthalmoscope comprising a camera and an associated illumination device; the invention further concerns a novel method for processing a plurality of images of the eye taken by said device; and software, typically included in said ophthalmoscope, for executing said method.

Abstract: The present invention relates to a phosphopeptide-stabilized amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complex, wherein the complex is formed at a pH of below 7.0. Methods of making such complexes are also provided. The complexes are useful in dental applications, in particular in dental remineralization.